Amphastar (AMPH) Q2 2026 Earnings Call Transcript
Amphastar (AMPH) reported Q2 2026 net revenues of $183.9 million, up 5% from $174.4 million, and gross margin of 50.8% versus 49.6%. GAAP net income was $30.3 million ($0.67/share). Adjusted non-GAAP net income was $40.8 million ($0.91/share). IMS remediation tied to an FDA warning letter is expected to add $2 million to $3 million per quarter, while full-year sales growth guidance remains mid-single digit to high single digit.
How this was made
The 30-second read
Why it matters
The key incremental trading input is management’s explicit expectation of higher quarterly IMS expenses ($2M to $3M) and possible sales slowing, which can compress near-term operating leverage. Offsetting factors include gross margin expansion and maintained annual sales growth guidance, plus a milestone payment tied to BAQSIMI net sales performance.
Market read
Traders can update near-term earnings models using the disclosed IMS remediation expense run-rate and the stated risk of future shutdowns, while monitoring whether gross margin expansion persists.
What to watch
The call notes capital spending is being redirected to IMS without changing overall CapEx profile, which could limit longer-term cash burn versus what investors may assume from remediation headlines.
Background
Amphastar’s Q2 2026 earnings call focused on product launch momentum and ongoing FDA-related remediation at its IMS facility after a warning letter.
Ticker impact
Amphastar reported Q2 results and guided IMS remediation expenses to rise $2M to $3M per quarter for several quarters, impacting margins and sales cadence.
Choppy-to-negative bias for the next few quarters as investors model higher IMS expense run-rate, with upside sensitivity to faster remediation progress and sustained gross margin.
The call discloses a specific incremental quarterly expense range and potential IMS sales slowing, both direct drivers of near-term profitability. Offsetting positives include gross margin expansion and maintained annual sales growth guidance, but the remediation language introduces uncertainty around timing and shutdown risk.
Market effects
Highlights execution and regulatory remediation risk for specialty pharma manufacturing sites, which can affect sector-wide sentiment on gross margin durability.
Limited direct regional impact; primarily US FDA-regulated manufacturing operations.
Low; the disclosed drivers are company-specific and US-focused (FDA warning letter, 340B dynamics).
Counterpoint
If IMS remediation milestones progress faster than expected, the $2M to $3M quarterly expense range could prove conservative, supporting a margin re-rating.
Key entities
- companyAmphastar Pharmaceuticals, Inc.
Subject of the earnings call transcript, reporting Q2 results and providing IMS remediation expense and sales cadence guidance.
- counterpartyEli Lilly
Will receive a $100M asset purchase milestone payment in Q3 2026 after BAQSIMI net sales reach a specified threshold.
- regulatorFDA
Issued a warning letter prompting IMS facility remediation and routine updates every one to two months.
